|
Abacavir, the antiretroviral drug sold under the brand name Ziagen by
GlaxoSmithKline, was invented by researchers at the University of Minnesota
with financial support from the federal government.
The University holds patent rights for Abacavir, and under a 1999 court
settlement, receives substantial royalties from GlaxoSmithKline on sales of
the drug. Students at the university are pressuring the administration to
adopt policies which would promote access to low-cost generic abacavir in
developing countries, rather policies which support GlaxoSmithKline's monopoly
on the drug.
Documents from the Students
Letters to University of Minnesota from NGOs Supporting the Students' Demands
General Information
News Stories